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2499–506.GRK2 Regulates
a2-Adrenergic Receptor–
Dependent Catecholamine
Release in Human Adrenal
Chromafﬁn CellsAlterations in catecholamine (CA) synthesis and
catabolism predispose to or aggravate the course of
cardiovascular disorders. In heart failure (HF),
excessive norepinephrine, resulting from persistent
sympathetic efferent ﬁber activation, contributes to
CA spillover, which is a major prognostic and thera-
peutic index (1).
Exaggerated epinephrine (EPI) from the chromafﬁn
cells of the adrenal glands (2) is also involved
in HF progression. EPI secretion is controlled by
b-adrenergic receptors (bARs), which facilitate its
release, and a2-adrenergic receptors (a2ARs), whichprovide negative feedback, preventing unremitted
EPI (and norepinephrine) adrenal discharge (1,2). In
chromafﬁn cells of HF rodents, G protein–coupled
receptor kinase 2 (GRK2) expression is up-regulated,
impairing a2AR-gated EPI secretion via desensitiza-
tion of these receptors (2). It is unknown whether a
similar mechanism is present in humans. Impor-
tantly, in ex vivo cultured human pheochromocy-
toma explants, gallein, a GRK2 inhibitor, prevents
uncontrolled CA secretion (3). However, it remains to
be determined whether physiologically relevant CA
concentrations can up-regulate GRK2 expression in
normal human adrenal glands, preventing sym-
pathoinhibitory a2AR effects on EPI (and norepi-
nephrine) release.
To this aim, we used human chromafﬁn cells iso-
lated from adrenal glands (n ¼ 13) from deceased
kidney transplant donors. The local ethics committee
of the University “Federico II” reviewed and
approved this protocol. All experimental methods
were described previously (2). Statistical signiﬁcance
was determined using the Student t test or analysis of
variance followed by Bonferroni post hoc correction
for multiple comparisons. All data were analyzed
using GraphPad Prism version 7 (GraphPad Software,
La Jolla, California).
We ﬁrst increased GRK2 expression and activity via
adenovirus (Ad), whereas in separate experiments we
expressed bARKct, an inhibitor peptide of GRK2
activation via Gbg sequestration. Noninfected cells, or
Ad–green ﬂuorescent protein (GFP) cells, were used
as controls. We stimulated human chromafﬁn cells
with nicotine to induce a marked EPI secretion; this
effect was equipotent in all experimental groups
(Figure 1A). Interestingly, pre-treating cells with the
selective a2AR agonist UK14304 resulted in an abated
nicotine-induced EPI release in control (CTR) and
AdGFP-infected cells (Figure 1A). However, the a2AR’s
sympathoinhibitory effect was markedly blunted in
AdGRK2-infected cells, whereas the presence of
bARKct potentiated it.
Stimulation with CA up-regulates GRK2 in the
heart (2). Similar direct evidence in human chro-
mafﬁn cells is lacking. Therefore, we pre-treated
in vitro human chromafﬁn cells with isoproterenol
(1 mmol/l) for 12 h and found a signiﬁcant rise in GRK2
protein levels (GRK2 levels fold over CTR, CTR 1.00 
0.04 vs. isoproterenol 1.88  0.42; p < 0.05 vs. CTR).
High GRK2 levels abolished the a2AR-mediated
negative feedback on EPI release, in both CTR and
GFP-expressing cells (Figure 1B). Importantly, bARKct
expression rescued a2AR-mediated inhibition on EPI
secretion from these human cells (Figure 1B).
FIGURE 1 In Vitro Modulation of Adrenal G Protein–Coupled Receptor Kinase 2 Activity Regulates Human Chromafﬁn Cell a2AR Function and
Thus Catecholamine Secretion
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Epinephrine (EPI) secretion, measured by enzyme-linked immunosorbent assay, from chromafﬁn cells isolated from human adrenal glands. (A) Cells were infected with
adenovirus–G protein–coupled receptor kinase 2 (AdGRK2) or adenovirus–b-adrenergic receptor Kct (AdbARKct). Noninfected cells (CTR) or adenovirus–green
ﬂuorescent protein (AdGFP)–infected cells were used as controls. Cells were stimulated with nicotine (20 mmol/l) for 30 min, following pre-treatment with vehicle or
with the a2-adrenergic receptor (a2AR) agonist UK14304 (10 mmol/l) for 30 min (*p < 0.05 vs. CTR þ nicotine; †p < 0.05 vs. CTR þ nicotine þ UK14304; n ¼ 6 per
group). (B) Cells were infected with AdbARKct. CTR or AdGFP-infected cells were used as controls. Twenty-four h post-infection, the cells were pre-treated with
isoproterenol (ISO) (1 mmol/l) for 12 h. Following ISO stimulation, the media were replaced, and the cells were stimulated with nicotine (20 mmol/l) for 30 min. After
ISO, and prior nicotine stimulation, a group of cells was pre-treated with the a2AR agonist UK14304 (10 mmol/l) (*p < 0.05 vs. ISO/CTR þ nicotine; n ¼ 6 per group).
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1516Our study is the ﬁrst to show that bAR-dependent
GRK2 up-regulation accounts for a2AR desensitiza-
tion in human chromafﬁn cells. GRK2 elevation
abolishes the feedback inhibition operated by a2AR
activation on further CA release from adrenal glands.
Our present ﬁndings offer a major advancement in
our understanding of the pathophysiology of diseases
characterized by elevated sympathetic nervous sys-
tem activity. At the same time, our data suggest that
GRK2 blockade could be useful in advanced human
HF as well as in other disorders aggravated by the
hyperactivity of the central and/or peripheral sym-
pathetic nervous system, namely, hyperthyroidism,
hypertension, and pheochromocytoma, all conditions
in which excessive circulating CA levels may be
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Ventricular Regional Wall
Motion Abnormality Can
Help Prevent Unnecessary
Ischemic WorkupI have read the paper by Dr. Doshi and colleagues (1)
with great interest, and I completely agree that a
better job can be done in identifying ischemic etiol-
ogy in new-onset heart failure. While deciding
who should undergo an ischemic workup, the
observation of a characteristic regional wall motion
pattern in dilated cardiomyopathy may be helpful
(2). In >40 patients with dilatative cardiomyopathy,
I observed inferior (2Ch [2chamber]) and inferolateral
(3Ch) akinesia with preserved contractility in
the proximal third of the inferolateral wall and in
the proximal third of the anterolateral wall
(4Ch), together with various degrees of hypocon-
tractility in the remainder of the left ventricle. None
of these patients had obstructive coronary artery
disease on coronary angiography. I believe that the
presence of this simple 2-dimensional echocardiog-
raphy parameter can help prevent unnecessary
ischemic workup in patients with new-onset heart
failure who do not have baseline coronary artery
disease.*Niksa Drinkovic, Jr., MD
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Regional Wall Motion Abnormality Can Help
Prevent Unnecessary Ischemic WorkupWe thank Dr. Drinkovic for his comments on our
study. Attempts to further explore noninvasive
methodologies to sufﬁciently differentiate between
nonischemic and ischemic etiologies of dilated
cardiomyopathy are of clear interest (14) because
they have the potential to obviate the need for
ischemic testing for selected patients. However,
identiﬁcation of ischemic etiologies for congestive
heart failure with reduced ejection fraction can lead
to treatment modiﬁcations (both related to secondary
preventive medical therapies and revascularization).
Furthermore, because revascularization of ischemic
cardiomyopathy has been associated with a survival
advantage over medical therapy alone (5), any such
methodology would be required to have sufﬁcient
negative predictive value so patients are not left
with a potentially reversible cause for heart failure
unaddressed or undiagnosed.Darshan Doshi, MD, MS
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